After years of CCHR campaigning, the FDA and foreign regulators wrote agitation, aggression, and even homicidal thoughts into the labeling of antidepressants, ADHD drugs, and other central nervous system prescription drugs.
By Jan Eastgate
President, CCHR International
September 4, 2026
In the wake of recent media reports and court cases linking psychiatric drugs to acts of senseless violence, CCHR International has released a compilation of international drug regulatory agency warnings and safety notices involving violence, aggression or hostility associated with some psychotropic drugs. These identify 57 notices since 2004, compared with five identified in 2004, and 13 of those notices specifically reference homicidal ideation or thoughts of harming others. The findings underscore the need for consumers to read psychotropic prescription drug package inserts for warnings and adverse reactions involving suicide, aggression and homicidal ideation. Prescribing physicians should explain those risks, even when they are listed as rare, because a label alone does not ensure informed consent. An uninformed patient should hold the prescriber accountable.
That accountability is no longer only a consumer demand. It is now being argued in courtrooms and conceded, uneasily, in the psychiatric press.
On August 27, 2026, Psychiatric Times published a self-critique, “Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?” It discussed a high-profile murder case in which the defense argued the client had been “overmedicated,” with a potentially violent result. The journal admitted that “a good portion of the public and the media appear to support the defense theory.” The defense argued that psychiatrists’ negligence led to the events. “The litigation places psychiatrists and other mental health providers under scrutiny, looking for possible errors or inconsistencies to demonstrate that they did not provide adequate care.” The authors asked: if a person is found not criminally responsible because of mental illness, can the psychiatrist then become responsible for the crime? They concluded that psychiatry risks being judged not by the quality of care, but by whether the patient had a good outcome—“and if we begin to judge psychiatric care by the crimes our patients commit rather than by the care we provide, psychiatry itself may end up on trial.”[1]
When the crime itself is blamed on the pill, one legal path is involuntary intoxication: the drug was taken as directed and the defendant did not know, and had no reason to know, of the specific intoxicating or psychotic effect. In a review of studied cases, the drugs most often cited were sedative-hypnotics and narcotics (45), antidepressants (18), and stimulants (6).[2]
That theory is being tested now. In the Lindsay Clancy murder trial, attorney Kevin Reddington argued the evidence supported an involuntary-intoxication instruction—overprescription, side effects, abrupt stops—and cited Commonwealth v. Wallace and related Massachusetts cases. He said the jury should be told it could treat the killings as manslaughter if the drugs, not a “mental disease or defect,” were the cause. Plymouth Superior Court Judge William F. Sullivan did not give a standalone involuntary-intoxication charge as a complete defense. He did let jurors consider prescription drugs when deciding intent and criminal responsibility, and he allowed manslaughter as a lesser included offense.[3]
Additionally, in deciding whether the defendant intended to kill the deceased and whether she formed that intent with deliberate premeditation, he told the jury, “you may consider any credible evidence that the defendant … was affected by her consumption of prescription drugs.” She may still form that intent while impaired or on those drugs, but the jury may weigh the evidence.[4]
A judge letting the jury hear about prescription drugs is not the same as a physician warning the patient before the first dose. A prescription drug label that lists violence or worsening mental state does not end that duty. Psychiatric Times, in “Preventing and Reducing Professional Liability Risk Related to Psychopharmacology,” tied the psychiatrist’s duty in part to the FDA’s March 22, 2004, public health advisory on worsening depression and suicidality, and to the 2004 boxed warning on antidepressants. Physicians must disclose what patients need to make informed decisions about psychotropic treatment.[5]
Federal courts have begun to say the same thing from the defendant’s side: print on a label does not automatically translate into knowledge. In United States v. Rainford (10th Cir., Dec. 9, 2025), the defendant was taking very high, off-label doses of the ADHD psychostimulant Adderall and killed a neighbor in a delusion that the man had abused his daughter. He raised involuntary intoxication, arguing that the stimulant caused a psychotic break he did not intend. The jury was told the label already warned of “possible intoxicating effects,” so he should have known the risk. On appeal, the Tenth Circuit disagreed. A general package warning is not the same as knowing one might become psychotic. If every label warning wiped out the defense, almost no one on a prescription could use it. The conviction was reversed and remanded for a new trial.[6]
The same stimulant-and-psychosis pattern appeared a generation earlier. In 1999, Ryan Ehlis was charged in North Dakota with murder after he shot his infant daughter and then himself. He had started Adderall about ten days earlier for ADHD. Prosecution and defense psychiatrists agreed he had an amphetamine-induced psychotic disorder and lacked criminal responsibility. The judge dismissed the charges, finding he lacked the capacity to understand what he was doing because of the drug. He was not treated as a continuing danger if he stayed off amphetamines.[7] That is involuntary intoxication from a prescribed stimulant: a temporary psychotic state that negated criminal responsibility.
Drug Regulatory Warnings of Suicide, Violence, and Homicide
Those courtroom fights did not arise in a vacuum. Concerns that SSRI antidepressants were linked to agitation, hostility, or violent thoughts—alongside suicidal thinking—circulated after fluoxetine (Prozac) and other SSRIs entered wide use in the 1990s. Since 1989, CCHR has been instrumental in raising awareness about these risks.
In 2003, there were five warnings listing suicide or suicidal ideation linked to psychiatric drugs. Today there are 82—a 1,266 percent increase. Fifty-nine of the 82 (72 percent) involve antidepressants.
On March 22, 2004, FDA issued a public health advisory that antidepressant treatment had been associated with anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia (severe restlessness), hypomania, and mania. Then, in October, the agency required a boxed warning on suicidality in children and adolescents, extended in 2007 to young adults through age 24. Hostility and aggressiveness stayed on the class “clinical worsening” list that patients and families were told to watch for.[8]
Around 2004, about 25 antidepressants were available in the United States. Today, about 38 antidepressant drugs are on the market.[9]
CCHR’s compilation of global drug regulatory agency warnings identifies 57 violence-, aggression-, or hostility-related warnings or safety notices since 2004, when there were five—a 1,040% increase. Of the 57 warnings, 13—nearly 22%—specifically cite homicidal ideation, homicidal thoughts, or thoughts of harming others.
The product labels followed the same path. Wyeth’s August 22, 2003, letter flagged pediatric hostility and suicidality with venlafaxine (Effexor).[10] In 2005, homicidal ideation was added to Effexor XR labeling.[11]
On July 1, 2009, FDA required a boxed neuropsychiatric warning for bupropion (Zyban, for smoking cessation) with matching language on Wellbutrin (an NDRI). Post-marketing reports listed homicidal ideation, hostility, agitation, aggression, psychosis, and suicidal events.[12]
On May 11, 2023, FDA required class-wide labeling changes for all prescription CNS stimulants, including amphetamine- and methylphenidate-containing products. Updated Drug Abuse and Dependence labeling states that “anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation” have been observed with stimulant abuse and/or misuse. FDA defined misuse broadly: using a drug for a therapeutic purpose other than as prescribed, or using a drug prescribed for someone else.[13]
When the antidepressant esketamine nasal spray (Spravato) was approved in 2019 for treatment-resistant depression, it had to be used with an oral antidepressant.[14] In January 2025, it was cleared for monotherapy and given antidepressant-class wording: patients should seek care at once for acting aggressive, angry, or violent; acting on dangerous impulses; new or worse irritability; or feeling very agitated or restless.[15]
FDA prescribing information for the antipsychotic aripiprazole (Abilify) lists “homicidal ideation” as a rare psychiatric adverse reaction in the premarketing evaluation of oral Abilify in adults—“rare” meaning fewer than 1 in 1,000 patients. Aripiprazole is sold as Abilify and in numerous FDA-approved generics.[16]
Taken together, U.S. labeling since 2004 shows wider official recognition that psychiatric drugs are associated with hostility, aggression, or, on some labels, homicidal ideation. That is label language.
However, printing the words is not the same as using and monitoring them. Tennessee’s 2025 law mandating toxicology screening for psychiatric drugs in acts of senseless violence is the appropriate response to the concern CCHR first raised in 1989, after the Kentucky mass shooting in which the coroner implicated Prozac in the perpetrator Joseph Wesbecker’s behavior.
The law means a government will now look, ask, and record whether the person was taking or coming off a psychotropic—so a drug factor that can be isolated and a future shooting, stabbing, or suicidal crash might be prevented instead of explained away.
The issue is also whether patients are adequately informed when regulators and manufacturers have identified potentially serious behavioral adverse effects—and whether prescribers are held accountable for ensuring that patients are warned about those risks. Consumers should be able to weigh the risks, recognize warning signs should they emerge, and seek prompt medical advice about concerning changes. They should not abruptly stop taking psychiatric drugs; any reduction or discontinuation should be undertaken with appropriate medical supervision.
Contemporary psychotropic labeling now states what CCHR warned for decades: these drugs can produce violent thoughts, aggression, and suicidal behavior. That language raises the duty, not lowers it. Consumers should read the warnings. Prescribing physicians and psychiatrists must disclose those violent and suicidal risks—and document that the patient received them in writing and heard them from the prescriber.
A label alone is not informed consent.
[1] Fernando Espí Forcén, MD, PhD, Susan Hatters Friedman, MD, MSt, DFAPA, “Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?” Psychiatric Times, 27 Aug. 2026, https://www.psychiatrictimes.com/view/psychiatry-on-trial-are-psychiatrists-responsible-for-their-patients-criminal-behavior
[2] Jennifer Piel, “The Defense of Involuntary Intoxication by Prescribed Medications: An Appellate Case Review,” Journal of the American Academy of Psychiatry and the Law Online, Sept. 2015, https://jaapl.org/content/43/3/321
[3] “Lindsay Clancy Trial Judge Considers ‘Involuntary Intoxication’ Jury Instruction,” YouTube, 20 Aug. 2026, https://www.youtube.com/watch?v=DTZs0kKaT_Q; “Judge Considers ‘Involuntary Intoxication’ Jury Instruction,” YouTube, 20 Aug. 2026, https://www.youtube.com/watch?v=z7SO5ClDnjE; “MA V. Lindsay Clancy Day 21,” Transcript, Rev, 27 Aug. 2026, https://www.rev.com/transcripts/ma-v-lindsay-clancy-day-21
[4] “Jury Can Consider Lindsay Clancy’s Prescription Meds When Deciding Intent,” YouTube, 27 Aug. 2026, https://www.youtube.com/watch?v=mMgYrMZYxpE https://www.youtube.com/watch?v=P8dQCC2OxSk
[5] “Preventing and Reducing Professional Liability Risk Related to Psychopharmacology,” Psychiatric Times, 1 Dec. 2005, https://www.psychiatrictimes.com/view/preventing-and-reducing-professional-liability-risk-related-psychopharmacology
[6] Reed Smith LLP, “High Dose Adderall Supports Defense of Involuntary Intoxication,” Lexology, 24 Dec. 2025, https://www.lexology.com/library/detail.aspx?g=8db5bfc7-ea6f-40a9-aa54-87cea8bd3437
[7] Sarah Boseley, “Family sues drug firm over baby killing,” The Guardian, 22 Sept. 2000, https://www.theguardian.com/uk/2000/sep/23/sarahboseley
[8] Jack Alan McCain, “Antidepressants and Suicide in Adolescents and Adults,” PubMed Central, July 2009, https://pmc.ncbi.nlm.nih.gov/articles/PMC2799109/; “Worsening Depression and Suicidality in Patients Being Treated With Antidepressant Medications,” FDA Public Health Advisory, 22 Mar. 2004; “Suicidality in Children and Adolescents Being Treated With Antidepressant Medications,” FDA Public Health Advisory, 15 Oct. 2004
[9] Jeffrey S. Harman, Ph.D., Mark J. Edlund, M.D., Ph.D., John C. Fortney, Ph.D., “Trends in Antidepressant Utilization From 2001 to 2004,” Psychiatry Online, May 2009; Zachary M. Sheffler, Preeti Patel, Sara Abdijadid, “Antidepressants,” StatPearls, Jan. 2026, https://www.ncbi.nlm.nih.gov/books/NBK538182/
[10] Evelyn Pringle, “TeenScreen – Normal Kids Labeled Mentally Ill,” Scoop Independent News, 2 Aug. 2006, http://www.scoop.co.nz/stories/HL0608/S00010.htm
[11] Effexor XR (venlafaxine hydrochloride) Extended-Release Capsules product label, Food and Drug Administration, https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020699s054%2C057lbl.pdf
[12] “Wellbutrin (bupropion hydrochloride) tablets and Sustained-Release tablets,” Food and Drug Administration, July 2009
[13] “FDA Drug Safety Communication: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions,” Food and Drug Administration, 11 May 2023
[14] “HIGHLIGHTS OF PRESCRIBING INFORMATION: SPRAVATO,” Food and Drug Administration, Mar. 2019
[15] “HIGHLIGHTS OF PRESCRIBING INFORMATION: SPRAVATO,” Food and Drug Administration, Jan. 2025
[16] “HIGHLIGHTS OF PRESCRIBING INFORMATION: ABILIFY,” Food and Drug Administration, Feb 2020
SHARE YOUR STORY/COMMENT